NEW YORK (GenomeWeb News) – Strand Genomics and BioHealth Innovation today announced a strategic partnership to expand the Strand Centers for Genomics and Personalized Medicine into the US.
As part of the deal, BHI will connect Strand with "key" market channels, providing patients and healthcare providers with access to genomic services. Based in Rockville, Md., BHI describes itself as an "innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets."
Financial and other terms of the deal were not disclosed.
Strand Genomics, a wholly owned subsidiary of Strand Life Sciences in Bangalore, India, provides bioinformatics products and services. The Strand Centers for Genomics and Personalized Medicine are clinical labs for sequencing-based diagnostic services.
In December, Strand Life Sciences announced a collaboration with El Camino Hospital in Mountain View, Calif., to create the Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital.